Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Associated Therapies: -

Clinical Trials

The Effect of Genetic Polymorphism on Interactions of Clopidogrel and Cilostazol in Healthy Volunteers

Not Applicable

Completed

Conditions: Interaction

Interventions: Drug: Clopidogrel
Drug: Cilostazol
Drug: Clopidogrel/Cilostazol

First Posted Date: 2011-11-30

Last Posted Date: 2013-06-03

Lead Sponsor: Inje University

Target Recruit Count: 28

Registration Number: NCT01482117

Drug Interaction Study of Clopidogrel and Rosuvastatin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rosuvastatin
Drug: Clopidogrel

First Posted Date: 2011-11-10

Last Posted Date: 2014-07-18

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 10

Registration Number: NCT01469416

Locations: 🇺🇸
Clinical Research Center, UCSF, San Francisco, California, United States

Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial

Phase 3

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Clopidogrel
Drug: prasugrel

First Posted Date: 2011-11-06

Last Posted Date: 2012-03-27

Lead Sponsor: Gennaro Sardella

Target Recruit Count: 30

Registration Number: NCT01465828

Locations: 🇮🇹
Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy

Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)

Phase 4

Completed

Conditions: Platelet Reactivity

Interventions: Drug: Clopidogrel
Drug: Prasugrel

First Posted Date: 2011-11-01

Last Posted Date: 2012-07-11

Lead Sponsor: University of Patras

Target Recruit Count: 27

Registration Number: NCT01463150

Locations: 🇬🇷
Cardiology Department Patras University Hospital, Rio, Achaia, Greece

Impact of CYP2C19*17 on the Pharmacokinetics of Proguanil and Clopidogrel

Phase 1

Completed

Conditions: CYP2C19 Genotypes

Interventions: Drug: Proguanil
Drug: Clopidogrel

First Posted Date: 2011-10-20

Last Posted Date: 2013-07-03

Lead Sponsor: University of Southern Denmark

Target Recruit Count: 31

Registration Number: NCT01456546

Locations: 🇩🇰
Clinical Pharmacology, University of Southern Denmark, Odense, Fyn, Denmark

Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study

Phase 4

Terminated

Conditions: Acute Coronary Syndrome
Cardiovascular Diseases

Interventions: Drug: clopidogrel
Drug: prasugrel

First Posted Date: 2011-10-14

Last Posted Date: 2022-03-16

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 9

Registration Number: NCT01452152

Locations: 🇺🇸
Christiana Care Health System, Newark, Delaware, United States
🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States
🇺🇸
Sinai Center for Thrombosis Research, Baltimore, Maryland, United States

and more 2 locations